Cipla Limited has announced its financial results for the second quarter of fiscal year 2027 (Q2FY27). The company reported total revenue from operations of ₹7,404 crore, with an EBITDA of ₹1,388 crore, resulting in an EBITDA margin of 18.7%. Profit After Tax (PAT) stood at ₹878 crore, with a PAT margin of 11.9%. The presentation highlights sustained business momentum and growth across key markets.
Cipla Reports Q2 FY27 Financial Performance
Cipla Limited has released its financial results for the second quarter ending September 30, 2026 (Q2FY27), showcasing consistent sequential growth in revenue and EBITDA. The company posted total revenue from operations of ₹7,404 crore for the quarter. EBITDA for Q2FY27 was recorded at ₹1,388 crore, with a corresponding margin of 18.7%. Profit After Tax (PAT) for the period was ₹878 crore, maintaining a PAT margin of 11.9%.
Business Performance Snapshot
The company’s performance was driven by growth across its key geographical segments. One India contributed ₹3,516 crore in revenue, marking a 12% year-on-year growth and achieving its highest-ever quarterly revenue. North America generated $172 million in revenue, benefiting from a U.S. FDA approval for gAdvair Diskus. One Africa reported $123 million, with private business growing 1.3x faster than the market. Emerging Markets & Europe achieved $101 million, demonstrating resilient performance amid geopolitical uncertainties.
Revenue Break-up and Key Highlights
The revenue break-up for Q2FY27 shows One India accounting for 48%, followed by North America at 22%, One Africa at 16%, and Emerging Markets & Europe at 13%. API and Others contributed 1%. Key market highlights include highest-ever quarterly revenue in One India, U.S. FDA approval for gAdvair Diskus in North America, and SA private growing faster than the market in One Africa.
Financial Performance Details (Q2FY27 vs Q2FY26)
In a year-on-year comparison, Total Revenue from Operations for Q2FY27 was ₹7,404 crore, down from ₹7,589 crore in Q2FY26. EBITDA decreased to ₹1,388 crore from ₹1,895 crore, with the EBITDA margin narrowing to 18.7% from 25.0%. PAT also saw a decrease to ₹878 crore from ₹1,351 crore, with the PAT margin at 11.9% compared to 17.8%. R&D expenses were ₹423 crore, representing 5.7% of revenue.
Consolidated Profit and Loss Summary
The consolidated profit and loss statement for Q2FY27 indicates revenue from sale of products at ₹7,368 crore. Total expenses amounted to ₹6,016 crore. Profit before tax was ₹1,177 crore, and after tax expenses of ₹321 crore, the profit for the period attributable to shareholders stood at ₹878 crore.
Consolidated Balance Sheet Summary
As of September 30, 2026 (Sep-26), the consolidated balance sheet shows Equity at ₹35,522 crore, Total Debt at ₹699 crore, and Inventory at ₹6,778 crore. Cash and Cash Equivalents were reported at ₹10,522 crore. Net Tangible Assets were ₹8,266 crore, and Goodwill and Intangibles stood at ₹7,107 crore.
Source: BSE
